In August and September, NCL testified before the Centers for Disease Control and Prevention (CDC) Advisory Committee of Immunization Practices (ACIP) in support of enhanced infrastructure for vaccine confidence and effective public health messaging. NCL’s Associate Director of Health Policy, Nissa Shaffi, expressed NCL’s historic support for vaccines and promotion of consumer awareness of their overwhelming safety and efficacy.
On October 22, Nissa Shaffi testified on behalf of NCL before the FDA’s Center for Biologics Evaluation and Research (CBER), Vaccines and Related Biological Products Advisory Committee (VRBPAC). The meeting was open to the public and its focus was the development, authorization and/or licensure of vaccines to prevent COVID-19. NCL testified in support of three standing priorities, which include safety and effectiveness of a COVID-19 vaccine, the responsible use of Emergency Use Authorizations (EUAs), and diversity in clinical trials. NCL submitted these comments for review by the Committee to ensure that consumers are afforded with safe and effective vaccines to combat the pandemic.